Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension

NCT04859582 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Withdrawn due to protocol amendment

Conditions

Stomach Neoplasms

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Cisplatin
DRUG: 5-fluorouracil
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Placebo for Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC